In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever

Abstract

Reverse vaccinology method was used to predict the monovalent peptide vaccine candidate to produce antibodies for therapeutic purpose and to predict tetravalent vaccine candidate to act as a common vaccine to cover all the dengue virus serotypes. Envelope (E)-proteins of DENV-1-4 serotypes were used for vaccine prediction using NCBI, Uniprot/Swissprot, Swiss-prot viewer, VaxiJen V2.0, TMHMM, BCPREDS, Propred-1, Propred and MHC Pred. E-proteins of DENV-1-4 serotypes were identified as antigen from which T cell epitopes, through B cell epitopes, were predicted to act as peptide vaccine candidates. Each selected T cell epitope of E-protein was confirmed to act as vaccine and to induce complementary antibody against particular serotype of dengue virus. Chimeric tetravalent vaccine was formed by the conjugation of four vaccines, each from four dengue serotypes to act as a common vaccine candidate for all the four dengue serotypes. It can be justifiably concluded that the monovalent 9-mer T cell epitope for each DENV serotype can be used to produce specific antibody against dengue virus and a chimeric common tetravalent vaccine candidate to yield a comparative vaccine to cover any of the four dengue virus serotype. This vaccine is expected to be highly immunogenic against dengue fever.

Keywords

dengue serotypes / dengue virus / vaccine / E-proteins / MHC I and II

References

[1] Ramesh V, Vijayakumar S. Homology and conservation of amino acids in E- protein sequences of dengue serotypes[J]. A Pac J Tro Dis, 2004; 4: 670–674.

[2] Abd Kadir SL, Yaakob H, Mohamed Zulkifli R. Potential anti-dengue medicinal plants: a review[J]. J Nat Med, 2013, 67(4): 677–689

[3] Dengue Fever. Health Protection Agency[EB/OL]. Natural Travel Health Network and Centre (NaTHNaC)[2017-12-18]. https://travelhealthpro.org.uk/pdfs/generate/factsheets.php?new=13.

[4] Ustafa M, EM. Illzam, Jeffree MS, Dengue fever: clinical spectrum, and management[J]. IOSR JDent Med Sci, 2017, 16:53–59.

[5] Stiasny K, Kössl C, Lepault J, Characterization of a structural intermediate of flavivirus membrane fusion[J]. PLoS Pathog, 2007, 3(2): e20

[6] Hidari KI, Suzuki T. Dengue virus receptor[J]. Trop Med Health, 2011, 39(4 Suppl): S37–S43.

[7] Goel A, Patel DN, Lakhani KK, Dengue fever—a dangerous foe[J]. J Ind Acad Clin Med, 2004, 5(3): 247–258.

[8] Muhamad M, Kee LY, Rahman NA, Antiviral actions of flavanoid-derived compounds on dengue virus type-2[J]. Int J Biol Sci, 2010, 6(3): 294–302.

[9] Peeling RW, Artsob H, Pelegrino JL, Evaluation of diagnostic tests: dengue[J]. Nat Rev Microbiol, 2010, 8(12 Suppl): S30–S38

[10] Rees CR, Costin JM, Fink RC, In vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries[J]. Antiviral Res, 2008, 80(2): 135–142.

[11] Brewoo JN, Kinney RM, Powell TD, Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice[J]. Vaccine, 2012, 30(8): 1513–1520

[12] Ambuel Y, Young G, Brewoo JN, A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates[J]. Front Immunol, 2014, 5: 263

[13] McArthur MA, Sztein MB, Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates[J]. Expert Rev Vacc, 2013, 12(8): 933–953.

[14] SIB Swiss Institute of Bioinformatics. UniProtKB/Swiss-Prot [EB/OL]. [2017-01-17]. http://us.expasy.org/sprot.

[15] Doytchinova IA, Flower DA. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines[J]. BMC Bioinformatics, 2007, 8: 4.

[16] Krogh A, Larsson B, von Heijne G, Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes[J]. J Mol Biol, 2001, 305(3): 567–580.

[17] Nazarian S, Mousavi Gargari SL, Rasooli I, An in silico chimeric multi subunit vaccine targeting virulence factors of enterotoxigenic Escherichia coli (ETEC) with its bacterial inbuilt adjuvant[J]. J Microbiolo Method, 2012, 90: 36–45.

[18] EL-Manzalawy Y, Dobbs D, Honavar V. On evaluating MHC-II binding peptide prediction methods[J]. PLoS One, 2008, 3(9): e3268

[19] Singh H, Raghava GP. ProPred1: prediction of promiscuous MHC Class-I binding sites[J]. Bioinformatics, 2003, 19(8): 1009–1014

[20] Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites[J]. Bioinformatics, 2001, 17(12): 1236–1237.

[21] Sturniolo T, Bono E, Ding J, Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices[J]. Nat Biotechnol, 1999, 17(6): 555–561.

[22] Guan P, Doytchinova IA, Flower DR. HLA-A3 supermotif defined by quantitative structure-activity relationship analysis[J]. Protein Eng, 2003, 16(1): 11–18

[23] Biomedical Informatics Network. T-EPITOPE designer[EB/OL]. [2009-10-16]. http://www.bioinformation.net/ted/.

[24] Kangueane P, Sakharkar MK, Rajaseger G, A framework to sub-type HLA supertypes[J]. Front Biosci, 2005, 10(1-3): 879–886

[25] Rodriguez-Roche R, Gould EA. Understanding the Dengue Viruses and Progress towards Their Control[J]. Biomed Res Int, 2013,13: 690835.

[26] Mayrose I, Penn O, Erez E, Pepitope: epitope mapping from affinity-selected peptides[J]. Bioinformatics, 2007, 23(23): 3244–3246.

[27] Wahala WM, Silva AM. The human antibody response to dengue virus infection[J]. Viruses, 2011, 3(12): 2374–2395.

[28] Racloz V, Ramsey R, Tong S, Surveillance of dengue fever virus: a review of epidemiological models and early warning systems[J]. PLoS Negl Trop Dis, 2012, 6(5): e1648

[29] Ilyas M, Rahman Z, Shamas S, Bioinformatics analysis of envelope glycoprotein E epitopes of Dengue virus type 3[J]. Afr J Biotechnol, 2011, 8: 3528–3533.

[30] Nielsen M, Lund O, Buus S, MHC class II epitope predictive algorithms[J]. Immunology, 2010, 130(3): 319– 328.

[31] Gao J, Kurgan L. Computational prediction of B cell epitopes from antigen sequences[J]. Methods Mol Biol, 2014, 1184: 197–215

[32] Sayeed U, Wadhwa G, Khan MK, An Immuno-informatics driven Epitope study from the molecular interaction of JEV non-structural (NS) proteins with Ribophorin (RPN)[J]. Bioinformation, 2014, 10(8): 496–501

[33] Sollner J, Grohmann R, Rapberger R, Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins[J]. Immunome Res, 2008, 4(1): 1–12

[34] Neema M, Karunasagar I, Karunsagar I. In silico identification and characterization of novel drug targets and outer membrane proteins in the fish pathogen Edwardsillatarda[J]. Bioinformatics, 2011, 3: 37–42.

[35] Taiwo AA, Falilat AJ, Ezemuel YS. Computational design of peptide vaccine against Acinetobacter baumannii infection using comparative genomic approach[J]. Compu Bio Bioinform, 2014, 2(1): 13–18.

[36] Liu J, Zhang W. Databases for B-cell epitopes[J]. Methods Mol Biol, 2014, 1184: 135–148

[37] Barh D, Misra AN. In silico Identification of membrane associated candidate drug targets in Neisseria gonorrheae[J]. Int J Integr Biol, 2009, 6: 65–67.

[38] Barh D, Misra AN, Kumar A, A novel strategy of epitope design in Neisseria gonorrhoeae[J]. Bioinformation, 2010, 5(2): 77–85.

[39] Somvanshi P, Seth PK. Prediction of T cell epitopes for the utility of vaccine development from structural proteins of dengue virus variants using in silico methods[J]. Ind J Biotechnol, 2009, 8: 193–198.

[40] Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: a reductionist view[J]. Virology, 2011, 411(2): 306–315

[41] Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines[J]. Vaccine, 2012, 30(29): 4301–4306.

[42] Bhatt S, Gething PW, Brady OJ, The global distribution and burden of dengue[J]. Nature, 2013, 496(7446): 504–507.

[43] Barh D, Kumar A. In silico identification of candidate drug and vaccine targets from various pathways in Neisseria gonorrhoeae[J]. In Silico Biol, 2009, 9(4): 225–231

[44] Eapen M, Rubinstein P, Zhang MJ, Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study[J]. Lancet, 2007, 369(9577): 1947–1954.

[45] Sakib MS, Islam MR, Hasan AK, Prediction of epitope-based peptides for the utility of vaccine development from fusion and glycoprotein of nipah virus using in silico approach[J]. Adv Bioinformatics, 2014, 2014: 402492.

[46] Meydan C, Otu HH, Sezerman OU. Prediction of peptides binding to MHC class I and II alleles by temporal motif mining[J]. BMC Bioinformatics, 2013, 14(Suppl 2): S13

[47] Robert DB, Homan J. Bioinformatic processes for determination of peptide binding: EP, EP2771349A2, WO2013040142A-3[P/OL]. [2014-09-03]. http://www.google.com/patents/EP2771349A2?cl=en.

[48] Upadhyay RK. Japanese encephalitis virus generated neurovirulence, antigenicity, and host immune responses[J]. ISRN Virology, 2013, 2013: 830396.

[49] Terry FE, Moise L, Martin RF, Time for T Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases[J]. Expert Rev Vacc, 2014, 1–15.

[50] Simmons M, Mora NT, Putnak R. Advances in the development of vaccines for dengue fever[J]. Vaccine (Auckl), 2014, 2: 1–14.

[51] Wan SW, Lin CF, Wang S, Current progress in dengue vaccines[J]. J Biomed Sci, 2013, 20(1): 37

[52] Ross TM, Tang XC, Lu HR, et al . COBRA based dengue tetravalent vaccine elicits neutralizing antibodies against all four dengue serotypes[J]. J Vacc Immunotechno, 2014, l(1): 1–7.

[53] Durbin AP, Kirkpatrick BD, Pierce KK, A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial[J]. J Infect Dis, 2013, 207(6): 957–965.

[54] Ansari S, Taylor-Robinson AW. Strategic approaches to multivalent vaccine development against Dengue virus infection[J]. Ann Vacci Immuni, 2014, 1: 1005–1012.

[55] Raviprakash K, Wang D, Ewing D, A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus[J]. J Virol, 2008, 82(14): 6927–6934

[56] Wilsona WW, DeLucasb LJ. Applications of the second virial coefficient: protein crystallization and solubility[J]. Acta Crystallogr F Struct Biol Commun, 2014, 70(5): 543–554.

[57] Pei-Yong SH. Molecular virology and control of flaviviruses[M]//Scott B. Halstead. Flavivirus Vaccines. Norfork, UK: Caister Academic Press, 2012: 185.

Acknowledgment

The authors are grateful to the DST-SERB (SB/YS/LS-109/2014) for providing financial assistance in this project. We specially express our thanks to the management of A.V.V.M. Sri Pushpam College (Autonomous), Poondi, for providing them necessary facilities and support to carry out this work.

RIGHTS & PERMISSIONS

2018 2018 by the Journal of Biomedical Research.